ATE168694T1 - Triantennar cluster glykoside, ihre herstellung und verwendung - Google Patents

Triantennar cluster glykoside, ihre herstellung und verwendung

Info

Publication number
ATE168694T1
ATE168694T1 AT93921124T AT93921124T ATE168694T1 AT E168694 T1 ATE168694 T1 AT E168694T1 AT 93921124 T AT93921124 T AT 93921124T AT 93921124 T AT93921124 T AT 93921124T AT E168694 T1 ATE168694 T1 AT E168694T1
Authority
AT
Austria
Prior art keywords
pct
cluster
date
triantennar
production
Prior art date
Application number
AT93921124T
Other languages
English (en)
Inventor
Ericus Anna Leonardus Biessen
Berkel Theodorus Josephus Van
Boom Jacobus Hubertus Van
Original Assignee
Univ Leiden
Nl Hartstichting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Nl Hartstichting filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE168694T1 publication Critical patent/ATE168694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT93921124T 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung ATE168694T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.

Publications (1)

Publication Number Publication Date
ATE168694T1 true ATE168694T1 (de) 1998-08-15

Family

ID=19861173

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921124T ATE168694T1 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung

Country Status (10)

Country Link
US (1) US5885968A (de)
EP (1) EP0655070B1 (de)
JP (1) JPH08502726A (de)
AT (1) ATE168694T1 (de)
AU (1) AU674160B2 (de)
DE (1) DE69319912T2 (de)
DK (1) DK0655070T3 (de)
ES (1) ES2122041T3 (de)
NL (1) NL9201440A (de)
WO (1) WO1994004545A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821001A4 (de) * 1995-03-31 2002-07-17 Drug Delivery System Inst Ltd Amidit- und oligonukleotidderivate
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
GB2372502B (en) * 2000-12-12 2004-10-13 Imperial College Carbohydrate compounds containing cholesterol and their use
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
RU2013117288A (ru) 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
BR112014004585A2 (pt) 2011-08-26 2017-06-13 Arrowhead Res Corp polímeros de poli(éster vinílico) para liberação de ácido nucleico in vivo
US20140100178A1 (en) * 2012-10-04 2014-04-10 Aslam Ansari Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
EP3591054A1 (de) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Gegen pcsk9 gerichtete antisense-oligomere und konjugate
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
CN108064313B (zh) 2015-03-17 2021-07-30 箭头药业股份有限公司 用于抑制因子xii的基因表达的组合物和方法
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
UY37146A (es) 2016-03-07 2017-09-29 Arrowhead Pharmaceuticals Inc Ligandos de direccionamiento para compuestos terapéuticos
CR20180432A (es) 2016-03-14 2018-11-21 Hoffmann La Roche Oligonucleótidos para reducir la expresión de pd-l1
EP3228326A1 (de) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleinsäure verbunden mit einem dreiwertigen glykokonjugat
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR102557906B1 (ko) 2016-09-02 2023-07-20 애로우헤드 파마슈티컬스 인코포레이티드 표적화 리간드
US10450565B2 (en) 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
WO2018185252A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Nucleic acid conjugates
EP3483269A1 (de) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produkte und zusammensetzungen
WO2018185241A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
EP3385380A1 (de) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produkte und zusammensetzungen
EP3385381A1 (de) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produkte und zusammensetzungen
EP3550022A1 (de) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produkte und zusammensetzungen
EP4219714A3 (de) 2017-04-05 2023-08-30 Silence Therapeutics GmbH Rna-interferenz-vermittelte hemmung von tmprss6
WO2018185253A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Ligand modified double-stranded nucleic acids
EP3385272A1 (de) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Weitere neuartige oligonukleotid-ligand-konjugate
US11414660B2 (en) 2017-04-05 2022-08-16 Silence Therapeutics Gmbh Products and compositions
CN111107853A (zh) 2017-09-11 2020-05-05 箭头药业股份有限公司 用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
TN2020000038A1 (en) 2017-09-14 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
KR102431353B1 (ko) 2017-10-16 2022-08-10 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
EP3697909A4 (de) 2017-10-17 2021-10-13 Arrowhead Pharmaceuticals, Inc. Rnai-mittel und zusammensetzungen zur hemmung der expression des asialoglycoproteinrezeptors 1
MA51707A (fr) 2017-11-13 2020-09-23 Silence Therapeutics Gmbh Acides nucléiques pour inhiber l'expression d'un gène cible comprenant des liaisons phosphorodithioate
EP3483270A1 (de) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produkte und zusammensetzungen
RS63955B1 (sr) 2017-11-13 2023-02-28 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiciju ekspresije lpa u ćeliji
CA3118327A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
EP3550021A1 (de) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produkte und zusammensetzungen für die inhibierung der expression eines zielgens
EP3775207A1 (de) 2018-04-05 2021-02-17 Silence Therapeutics GmbH Sirnas mit vinylphosphonat am 5' -ende des antisense-strangs
WO2020007892A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
EP3598995A1 (de) 2018-07-26 2020-01-29 Silence Therapeutics GmbH Produkte und zusammensetzungen
EP3844274A1 (de) 2018-08-28 2021-07-07 Roche Innovation Center Copenhagen A/S Neoantigen-engineering unter verwendung von spleissmodulierenden verbindungen
PL3880818T3 (pl) 2018-11-13 2023-01-23 Silence Therapeutics Gmbh Kwasy nukleinowe do hamowania ekspresji LPA w komórce
EP3730617A1 (de) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nukleinsäure zur hemmung der expression von c3 in einer zelle
US20220017899A1 (en) 2018-11-23 2022-01-20 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
JP2022521155A (ja) 2019-02-07 2022-04-06 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
WO2020173845A1 (en) 2019-02-26 2020-09-03 Roche Innovation Center Copenhagen A/S Oligonucleotide formulation method
JP2022531874A (ja) 2019-05-07 2022-07-12 ウニベルジテート ベルン 細胞におけるｐｒｏｓ１の発現を阻害するための核酸
US20220305046A1 (en) 2019-06-06 2022-09-29 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
JP2022536945A (ja) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
BR112022003513A2 (pt) 2019-08-27 2022-05-17 Silence Therapeutics Gmbh Ácidos nucleicos para inibição da expressão de c3 em uma célula
JP2023509870A (ja) 2019-12-24 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー Ｈｂｖの処置のためのｈｂｖを標的とする治療用オリゴヌクレオチドとｔｌｒ７アゴニストとの医薬組合せ
EP4081217A1 (de) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmazeutische kombination von antivirusmitteln, die hbv und/oder einen immunmodulator zur behandlung von hbv steuern
JP2023519246A (ja) 2020-03-26 2023-05-10 アローヘッド ファーマシューティカルズ インコーポレイテッド ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法
KR20230018429A (ko) 2020-05-27 2023-02-07 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 세포에서 cnnm4의 발현을 억제하기 위한 핵산
JP2023541170A (ja) 2020-09-15 2023-09-28 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｚ－ａａｔタンパク質のレベルを低下させる方法
WO2022096424A1 (en) 2020-11-04 2022-05-12 Universität Bern Nucleic acids for inhibiting expression of pros1 in a cell
WO2022184852A1 (en) 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
WO2022223557A1 (en) 2021-04-20 2022-10-27 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of xdh in a cell
WO2022229150A1 (en) 2021-04-27 2022-11-03 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treawtment of myeloproliferative disorders
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
AU2022336157A1 (en) 2021-09-02 2024-03-14 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US751219A (en) * 1904-02-02 Leaf-turner
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
FR2637185A1 (fr) * 1988-10-05 1990-04-06 Ire Celltarg Sa Vecteurs synthetiques de faible poids moleculaire, utilisation en therapie ciblee et en imagerie medicale et procedes de preparation
ES2147216T3 (es) * 1993-09-01 2000-09-01 Akzo Nobel Nv Bisconjugados que comprenden dos sacaridos y un grupo de union.

Also Published As

Publication number Publication date
DK0655070T3 (da) 1999-04-26
DE69319912T2 (de) 1999-04-15
WO1994004545A1 (en) 1994-03-03
DE69319912D1 (de) 1998-08-27
EP0655070A1 (de) 1995-05-31
NL9201440A (nl) 1994-03-01
JPH08502726A (ja) 1996-03-26
ES2122041T3 (es) 1998-12-16
AU4835593A (en) 1994-03-15
AU674160B2 (en) 1996-12-12
EP0655070B1 (de) 1998-07-22
US5885968A (en) 1999-03-23

Similar Documents

Publication Publication Date Title
DE69319912D1 (de) Triantennar cluster glykoside, ihre herstellung und verwendung
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
IT1276071B1 (it) Compositi ad attivita' anti-infiammatoria
FI964789A (fi) Elastaasin pefluorialkyyliketoni-inhibiittoreita ja menetelmiä niiden valmistamiseksi
FI952607A (fi) Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi
DE59409794D1 (de) Benzoylguanidine, ihre herstellung und ihre verwendung in arzneimitteln
NO2012003I1 (no) 4-aminopyridin eller et derivat derav
ES2102475T3 (es) Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
DK1042340T3 (da) 6-O-alkylerythromycinoxim-B
NO980317L (no) Anvendelse av Calendula-glykosider for behandling av psoriasis
ATE71113T1 (de) Antibiotikum a 40926 mannosyl aglycon.
DE69230037T2 (de) Kontinuierliche zellinie sowie impfstoff gegen geflügelinfektion mit kokkidien
FI88509C (fi) 9-alfa,11-beta-nitro-substituerade och 11-beta-nitro-substituerade estraner
SE8702188L (sv) Farmaceutiska kompositioner
DE68918944D1 (de) Künstliche rezeptor-analoge.
DE69022845T2 (de) Erythromycinderivate.
MX9301235A (es) DERIVADOS 1,4-DIOXINO(2,3-B)PIRIDINA. á
NO304754B1 (no) Modulkanalsystem med et tverrsnitt med avrundete hjoerner
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
DE69323191D1 (de) Wasserlösliche retinoide
ATE174509T1 (de) Metabolisierbarer plasmaersatz
Highsmith et al. Clinical microbiology newsletter.
SU1513867A1 (ru) 2,2'-азобис{2-циано-5-[6-или(4-метил-3)(2,3-эпоксипропоксикарбамино)гексил - или (фенил)аминокарбокси]пентаны} в качестве промежуточных продуктов для получения эпоксидных олигомеров

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee